Thanks for your words of wisdom. I agree with everything you posted today. Most people have no concept of the complexities and pitfall of getting a drug approved and why regulators may differ in their opinion from the company's technical and medical advisory boards, without their being fraud or gross incompetence involved. At least ARIAD recovered much faster than any company in memory from a clinical hold, and with visible support from the patients and the medical experts as to the value of the ponatinib and its potential.
The valuation to be attributed to that IP will be the problem---one of the most difficult tasks if there are little or no sales of products, processes, etc protected by the grant to exclude others encompassed by that IP.
News 
Market Data 
Discover 
